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Pregnancy is characterized by hormonal changes, critical for the mother’s 
physiological adaptation, exercising a role in the fetus’s development, maintenance, 
protection, and nutrition. Since born, the neuroendocrine system’s involvement is 
necessary to prevent the embryo from being rejected by the mother’s immune sys-
tem. These changes are regulated by fluctuations in hormones such as Progesterone, 
Testosterone, Androstenedione, Dehydroepiandrosterone, Estradiol, Prolactin, 
human Placental Lactogen, human Chorionic Gonadotropin, and Thyroid hor-
mones, which promote the mother’s development and the fetus (maternal-fetal 
development). Therefore, given the great importance of these hormones during 
pregnancy, this chapter will explain the preclinical and clinical participation of sex 
hormones in maternal-fetal development.
Keywords: pregnancy, hormonal changes, maternal-fetal development
1. Introduction
During pregnancy, the neuroendocrine system undergoes significant hormonal 
fluctuations determined by stimulatory and inhibitory inputs from the mother 
and fetus to maintain the internal environment (milieu). This process is regulated 
mainly by both the maternal brain and the placenta, acting through the maternal-
placental-fetal unit (MPFU). It also serves as a protection system against stress and 
immune responses [1, 2].
Interestingly, the neuroendocrine responses generate a feedback circuit  regulated 
by the placenta. This organ begins its development in days six-seven after conception. 
It has been considered a passive organ for many years, acting as a barrier between the 
mother and the fetus, provide nourishing and eliminate metabolism products such 
as urea, uric acid, and creatinine. However, the placenta is a neuroendocrine organ 
that can synthesize and release hormones, neuroactive factors, and other mediators, 
allowing the proper development of the fetus’s maternal tissues to ensure an optimal 
pregnancy, allowing the fetus to adapt and survive under conditions of stress, infec-
tions, hypoxia, and malnutrition [3, 4]. This neuroendocrine mechanism involves at 
least three different endocrine axes; the hypothalamus-pituitary-gonads axis (HPG), 
the hypothalamus-pituitary–adrenal gland axis (HPA), and the hypothalamus-
pituitary-thyroid axis (HPT), to ensure optimal maternal-fetal development [1].
Specifically, the HPG axis, which is the central axis involved in regulating 
the reproductive function in vertebrates by a releasing pulsing of GnRH at the 
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hypothalamus and placenta, has a decisive role in the different stages of pregnancy. 
In this sense, it plays a central role in regulating MPFU development through posi-
tive and negative regulation of sex hormones [1].
2.  Gonadotropin-releasing hormone (GnRH), FSH, and LH, primary 
mediators of sex hormones releasing
The GnRH is a hormone synthesized by the hypothalamic neurons. It travels 
through the portal-pituitary-system to bind to its receptors (GnRHR-I) in pituitary 
cells (gonadotrophs), activating the synthesis of FSH (Follicle-stimulating hormone) 
and LH (Luteinizing hormone). These hormones are released into the systemic circula-
tion to act on sex organs regulating both oogenesis and spermatogenesis. Interestingly, 
GnRH isoforms (GnRH-I and GnRH-II) have also been identified in other tissues, 
including the testicles, prostate, mammary gland, endometrium, and placenta. In these 
organs, it has been shown that GnRH-II acts by binding to GnRHR-II receptors [5].
The functions associated with these isoforms are the production of the β-human 
chorionic gonadotropin (β-hCG) by the syncytiotrophoblast in the early stages of 
pregnancy. Here, β-hCG intervenes in at least two vital functions, avoiding lute-
olysis and ensuring Progesterone’s production (P4) until the placenta is implanted. 
Thus, specific conditions that interfere with this endocrine axis before weeks seven 
to nine of gestation would culminate in pregnancy loss [5].
Moreover, recent evidence indicates that GnRH is involved in the maternal-fetal 
environment’s remodeling (milieu) that allows the fetus’s correct implantation. This 
process is accompanied by increased proliferation of trophoblasts, which invade 
the decidua and form the outer and inner layers of syncytiotrophoblast, directly 
contacting maternal tissue. In this condition, the expression of specific metal-
loproteinases (MMP) is affected. Preclinical studies have shown that both isoforms 
(GnRH-I and GnRH-II) modify cellular matrix metalloproteinases’ expression. Two 
of them, MMP-2 and MMP-9, are the most directly involved in the migration and 
invasion of trophoblasts [5].
In addition to the above, it has been shown that both isoforms can produce 
proangiogenic cytokines, playing a central role in the rerouting of immune system 
cells involved in the restructuring of the arteries in the maternal-fetal interface [5]. 
Therefore, GnRH’s direct participation is vital for all physiological, hormonal, and 
structural changes that will culminate in the fetus’s correct implantation.
On the other hand, GnRH causes the stimulation of the pituitary hormone’s 
LH and FSH to regulate the sexual function. However, preclinical studies showed 
that both hormones are inhibited because of Progesterone and Estrogen increased 
production during pregnancy. Moreover, FSH and LH level rises on day ten after 
birth, which correlates to the decrease in sex hormones. In this sense, it has been 
established that the reduction of sex hormones after delivery performs negative 
feedback, which can achieve the complete reestablishment of reproductive function 
two months later after birth [6].
Interestingly, these data provide information valuable in understanding the posi-
tive and negative feedback mechanisms that play the sexual hormones during the 
pregnancy to maintain the MPFU.
3. Progesterone, the “pregnancy hormone”
Progesterone (P4) is considered the “pregnancy hormone” because it is critical for 
gestational maintenance [3]. During this stage, P4 is produced mainly by the ovary’s 
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luteal body until the twelfth week of pregnancy. After that, its release is principally 
maintained by the placenta, reaching levels of up to 3 μg/g, while blood concentra-
tions range from 100 to 500 nM, being four to six times its basal levels [7, 8]. These 
values rise significantly as gestational age progresses. It is involved in both the main-
tenance and development of the endometrium and inhibiting the uterus’ smooth 
muscle from preventing premature contractions (spontaneous abortion) [8].
Interestingly, the increase in this hormone’s levels seems to be regulated by an 
independent mechanism that generally restricts the synthesis of this hormone, 
being produced by the placental trophoblast cells in response to the stimuli 
produced in the uterine-fetal microenvironment [9]. At this level, its synthesis 
is carried out by converting the maternal cholesterol to the pro-hormone preg-
nenolone into the mitochondrial cytochrome P450. After that, by the action of 
3-β-hydroxysteroid dehydrogenases (HSD), it is metabolized to Progesterone. Of 
the total synthesized Progesterone, 90% go into the maternal circulation, and the 
remaining 10% goes into fetal circulation [10].
Placental P4 plays an essential role in establishing a pregnancy, as it is respon-
sible for inhibiting uterine contractions that occur at the myometrium’s smooth 
muscle. In this context, the deficiency of this hormone during the luteal phase has 
been widely related to infertility and loss of the pregnancy, presenting abortion, a 
situation that can occur at any stage of pregnancy [8, 9]. Besides, it is involved in 
the formation of decidua (a layer that coats the endometrium). In this sense, P4 is 
involved in the structural changes that the uterus undergoes during this period by 
increasing blood vessels’ permeability and endometrial density. Moreover, it has 
been suggested that the increase in decidual density is related to a lower likelihood 
of miscarriage. Also, P4 ensures the integrity of the fetus-maternal interface during 
the process of trophoblastic invasion and placenta formation [8, 11, 12]. What is 
more, P4 blocks the early production of T-cell lymphopoiesis protective role intra-
uterine environment’s immune system (milieu). For that reason, it has been sug-
gested that Progesterone acts as an immunosteroid since a satisfactory pregnancy 
depends on maternal tolerance to the fetal ‘semi-allograft’ [8].
Similarly, it has been suggested that the increase in P4 levels induces changes in 
gene expression in the uterine endometrium, indirectly favoring embryo growth 
[12]. Furthermore, it is a crucial factor between the endocrine and immune system 
since it has been shown that this hormone is involved in the implantation of tissue, 
preventing it from being rejected by the mother, a mechanism that appears to be 
mediated by Th cells (helper T cells), as well as by the interleukins (IL) IL-3, IL-4, 
IL-5, and IL-10, in such a way, it has been suggested that through inhibition of Th 
1 cells and increased production of interleukins, Progesterone is involved in the 
implantation of the fetus and its maintenance [7, 8].
On the other hand, P4 is involved in regulating the expression of uterine den-
dritic cells. These are known as antigen-presenting cells (APCs) involved in innate 
immune response and tolerance maintenance. However, in immature stages, these 
cells have a tolerogenic phenotype characterized by the low expression of co-stimu-
lating molecules and pro-inflammatory cytokines. Thereby, it has been shown that 
in the early stages of pregnancy, Progesterone prevents dendritic cells’ maturation. 
All these previous actions contributed to the maintenance of pregnancy [8].
More interesting, it has been shown that P4 is also involved in reducing ges-
tational stress. In this sense, it has been shown that it can over-express the mPRα 
gene, which encodes for a membrane receptor present in Cytolytic T lymphocytes 
CD8 + T cells, and whose increase has been linked to a protective effect against 
stress-induced abortion [7].
Finally, it is known that P4 levels decrease at the end of pregnancy, a phenom-
enon that is related to the onset of labor. Hence, an excellent regulatory mechanism 
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of P4 (both at the endocrine and immunological level) from the beginning to the 
culmination of pregnancy, it is necessary to the implantation, maintenance, and 
completion of this [12, 13].
4.  The modulatory hormones in pregnancy; testosterone (T), 
androstenedione (A4), and dehydroepiandrosterone (DHEA)
The androgenic hormones T, A4, and DHEA, plays a central role in regulating 
reproductive processes in many mammalian species. Besides, the presence of andro-
gen receptors has also been demonstrated in different tissues such as the ovary, the 
myometrium, and placenta, where they are known to participate in implanting the 
fetus and placentation. In this sense, it has been shown that, once pregnancy occurs, 
androgen synthesis takes place in the small luteal cells (SLC) of the corpus luteum 
by stimulation of the human chorionic gonadotrophin (hCG) [3, 14]. In addition 
to the above, once the placenta has been established, it becomes an independent 
androgen production source [14]. In this aspect, placental syncytiotrophoblast uses 
the circulating DHEA, provided by the maternal and fetal adrenal glands, turning 
it into A4 and T. Which, in turn, as will be discussed later, can be converted to estro-
gens by different routes to regulate embryonic development [3, 15]. Interestingly, it 
has been suggested that myometrium could be another important source of andro-
gens during pregnancy; a recent in vitro study showed that this tissue could also 
produce T and A4 [15].
Suppressively, these hormones are coordinated synthesized during pregnancy. 
Specifically, it has been shown that T levels increase in the first trimester of preg-
nancy, reaching a plateau in the second trimester, to later decrease slightly, rising 
considerably in the last month of pregnancy [14, 15]. Concerning A4, the study 
carried out by Satué et al. (2018) in mares shows that this hormone rises during ges-
tation, from the second month of pregnancy, reaching a peak maximum in the first 
stage of pregnancy, and, in the second state, it reduces significantly, reaching its 
lowest levels in the last month of gestation. However, a clinical study conducted by 
Makieva et al. (2014) showed that A4 remains stable throughout pregnancy without 
significant fluctuations. About DHEA, it increases progressively from the first to 
the fifth month of pregnancy, reaches its highest levels, then begins to decrease 
between months 6 and 7, reaching its lowest levels in the last month of pregnancy 
in mares, which is agree with the observed in pregnant women, with levels up to 
50% lower than those observed in non-pregnant women, an effect associated with 
negative E2 feedback to the maternal adrenal glands [14, 15].
The fluctuations in these hormones have specific functions during pregnancy. 
The significant increase observed in the first months of gestation is associated 
with the function of the corpus luteum, which uses T for estrogens’ production 
(analyzed in the next topic), regulating the implantation and decidualization. 
Later, the decrease observed in the middle of the gestation is related significantly 
to the development of the fetal gonads, providing the necessary substrates for the 
synthesis of placental estrogens. So, the primary site of estrogen synthesis at this 
stage could be the fetus. Finally, T’s elevation in the last stage of pregnancy, but not 
of A4 and DHEA, could be associated with the restructuring that the cervix must 
undergo to be prepared for the moment of delivery. At this stage, it has been shown 
that the cervix can  convert T into another metabolite, Dihydrotestosterone (DHT), 
through the action of 5-alpha-reductase. This androgen is involved in restructuring 
the cervix’s extracellular matrix tissue, including the structural changes that allow 
the myometrium’s contractility [14, 15].
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Therefore, these interesting data confirm the surprising interrelation and 
interdependence between estrogens and androgens produced by MPFU to protect 
and ensure pregnancy’s proper development.
5. Estrogens in pregnancy, an orchestral regulatory mechanism
Estrogens are a group of four different steroid hormones: Oestrone (E1), 
17β-Oestradiol (E2), Oestriol (E3), and Oesterol (E4), cyclically synthesized in 
response to changes during the ovarian cycle, specifically during the pre-ovulation 
phase, favoring folliculogenesis. However, estrogens also play a central role in the 
growth of the uterus and mammary gland. It increases the blood flow indispensable 
for transporting nutrients between the uterus and the fetus [16]. During pregnancy 
and up to the time of delivery, significant amounts of estrogens are released by the 
maternal-fetus-placental unit, formed by the luteal body, placenta, and the fetal 
adrenal cortex [3], suffering significant adjustments between the weeks seven to 
nine of pregnancy, reaching its highest levels at the time of delivery [17, 18].
17β-Oestradiol (E2) is the most abundant hormone synthesized during preg-
nancy. In connection with this, until the third month of pregnancy, significant 
levels of E2 are released by the luteal body, a period from which the primary site of 
estrogen production is the placenta [3]. It should be noted that the placenta has no 
autonomic innervation, so these increases occur in response to close communica-
tion between the mother and the fetus, where the hormone acts in an autocrine-
paracrine form in the development of the mammary gland and uterus, as well as in 
the development of sexual characteristics in the fetus. This connection allows the 
placenta and fetus to exchange and share steroid precursors, thus achieving their 
hormonal self-regulation [18].
Several studies have shown that the increase in estrogen levels is the result of a 
mutual exchange between the mother and placenta, in which the placenta uses the 
circulating androgen DHEA produced by the adrenal glands of the MPFU, where 
it is converted to Testosterone and Androstenedione and then metabolized to E1 
and E2 with the help of the cytochrome cyp450 aromatase enzyme [3, 7]. In such a 
way, both the mother and the fetus contribute to the increase in estrogen synthesis, 
regulating their production. In addition to this, and due to the high maintenance 
of this hormone throughout pregnancy, there is sufficient evidence to suggest that 
regulation in levels of this hormone could also be at the neural level, where E2 could 
act as a trigger factor of the HPA gland axis. So, the adaptive changes that occur 
in the mother-fetus are regulated by a positive feedback mechanism, in which the 
binding of E2 to their receptors at the brain could be sending signals to the adrenal 
glands for producing a more significant amount of DHEA, thus maintaining their 
constant levels [19]. Therefore, it seems clear that estrogen levels regulation during 
pregnancy occurs both locally, by an interaction of the placental-fetal unit and in an 
autonomic way, with the direct participation of the Central Nervous System.
Concerning its functions, estrogen has been shown to act through binding to 
nuclear receptors, participating in multiple processes to ensure the maintenance 
of pregnancy having different roles: in human endometrial explant cultures, they 
are involved in uterine vascular restructuring by binding to their nuclear recep-
tors present in epithelial and stromal cells of the cervix and endometrium, acting 
regulating the expression of different genes that control intrauterine growth, matu-
ration of vital organs such as mammary glands for breastfeeding and childbirth 
[16–18, 20]. Besides, it promotes the processes of angiogenesis and vasodilation that 
allow the transfer and exchange of nutrients and oxygen between the placenta and 
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the fetus through uterine and fetal circulation, a process associated with an increase 
in endothelial production of nitric oxide [3, 21].
On the other hand, in the primary culture of endometrial-epithelial cells (ESC), 
it has been found that E2 plays an essential role at the beginning of pregnancy by 
acting in processes such as differentiation and cell proliferation through the secre-
tion of insulin growth factor type 1 (IGF-1) [22]. Also, it increases the rate at which 
the fertilized egg travels through the fallopian tube, so low estrogen levels promote 
ectopic pregnancies because the egg stays longer in the fallopian tube [23].
In addition to the above, estrogens E1, E3, and E4, also, play a central role in 
pregnancy. E1 is the most abundant conjugated estrogen (estrone sulfate) during 
pregnancy; it increases from the first trimester of pregnancy, reaching its maximum 
peak in the 35th week of gestation; among its functions, the decrease of estrogenic-
ity has been indicated in the time of delivery [24]. E3 (Oestriol) is also considered 
a derivative of estradiol, whose primary role during pregnancy is increased utero-
placental blood flow during pregnancy. However, a specific function has also been 
suggested in the induction of myometrial cells’ contractions through the increase 
of connexin-4, allowing the restructuring of the myometrium that will trigger the 
initiation of labor [3]. On the other hand, Oesterol (E4) has an uncertain function 
during pregnancy since it is produced exclusively by the fetal liver starting up from 
the ninth week of pregnancy, reaching its significantly elevated levels after week 
30, with a peak at week 40. Although its function is unclear, preclinical studies have 
shown that it can bind to estrogen and progesterone receptors at the uterus, produc-
ing histological structural changes and biochemical fluctuations, essential during 
the differentiation of endometrial cells in pregnancy and delivery [25].
Therefore, during pregnancy, the hyperestrogenic state plays a significant role 
in maternal-fetal development, being a key piece in fetal growth. Hence, all these 
actions make the estrogen pleiotropic essential hormones in pregnancy.
6. Prolactin in pregnancy, more than a lactation hormone
Prolactin (PRL) is a protein hormone synthesized by the lactotroph cells of the 
anterior pituitary gland. Unlike other pituitary hormones, its release is inhibited by 
Dopamine (DA), a hypothalamic factor produced by dopaminergic neurons located 
in the arcuate nucleus, which has not only been shown to be able to regulate the 
release of PRL but can act at the lactotrophic cells, regulating their proliferation [1]. 
In addition, PRL can control its release, directly stimulating dopaminergic neurons 
and through direct and indirect mechanisms regulated by E2 [23].
In this sense, a preclinical rat model study showed that in the different repro-
ductive stages, PRL intervenes in a coordinated manner with E2 and Dopamine 
in regulating the proliferative activity of lactotrophic cells. In this collaborative 
process, these cells’ activity is elevated in the estrus and delivery stages. But it is 
decreased during the early stages of pregnancy and lactation, even though PRL 
levels are increased in all these reproductive stages. In this context, it has been sug-
gested that E2 participates in stimulating the release of PRL during the early stages 
of pregnancy and lactation by acting at the hypothalamic level regulating both the 
increase in prolactin levels and the activity of the lactotroph cells when DA is not 
present, play a dual role in the release of this hormone [23, 26].
Evermore, during pregnancy, essential adaptations occur to allow the release of 
significant amounts of this hormone by the stimulation caused by the mammary 
gland and the luteal body [27], with substantial elevations from the twentieth week 
of pregnancy, until after childbirth [26]. Specifically, PRL has been shown to play a 
vital role in regulating IL-10 and IL-12 interleukins (essential regulators of immune 
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responses during inflammatory processes). On the one hand, IL-12 interleukin has a 
pro-inflammatory function, activating itself in response to situations such as stress. 
On the other hand, IL-10 is an anti-inflammatory cytokine, which intervenes in the 
regulation of the expression of IL-12. In this sense, it has been shown that, during 
pregnancy, PRL increases the concentration of IL-10, an effect suggested is associ-
ated with the proper maintenance of this [28].
At the clinical level, this hormone has been shown to provide luteotropic support 
to the luteal body by intervening in the biosynthesis of P4 for its maintenance in the 
first three months of pregnancy, having an indirect function in the implantation of 
fetus in the uterus, as well as in the induction of vascular factors necessary for the 
increase in the volume of the luteal body [1, 29]. On the other hand, it acts directly 
on the mammary gland, determining the growth and development of alveoli, 
promoting the expression of genes related to milk synthesis and lactopoiesis. It also 
helps maintain the luteal body’s integrity and decidual cell survival [30]. Moreover, 
it is involved in the synthesis of relaxin, a hormone responsible for dilating the 
cervix during labor, thus facilitating the fetus’s expulsion [27].
PRL, it has been shown to play an essential role in regulating leptins expression 
in the gestational stage [31]. Leptins are hormones produced mostly by adipocytes, 
whose central role is related to the regulation of body weight, appetite, and energy 
homeostasis. The increase in their plasma levels is associated with the rise in the 
amount of body fat. However, during the gestational stage, vast quantities of leptins 
are released by the ovary and placenta, remaining constant throughout pregnancy, 
intervening in the regulation of fetal weight and growth, and with the develop-
ment of gestational diabetes [32]. In this sense, the increase in PRL levels has been 
suggested to inhibit the receptor to leptins (LepR), thus blocking the signaling 
pathways that regulate the development of gestational diabetes [31].
Finally, it has a central role in mother–child recognition by increasing the 
generation of neurons at the olfactory bulb level, which is essential for such recog-
nition [29]. For that reason, PRL recognizes like a multifaceted hormone, with dual 
actions during and after delivery.
7.  Human placental lactogen, an exclusive metabolic hormone  
in pregnancy
The human placental lactogen hormone (hPL), known as human Chorionic 
somatomammotropin, is a polypeptide hormone elevated during pregnancy and is 
produced exclusively by the placenta [3]. hPL levels are detected between the first 
and second weeks of placenta gestation. However, it is released into the maternal 
circulation between the third to sixth week of pregnancy, being possible its detec-
tion, which increases until reaching its constant levels with a significant increase at 
the end of pregnancy with substantial effects after delivery [3].
Although there is controversy regarding its participation during pregnancy, it 
has been suggested that its primary function is the regulation of maternal metabo-
lism of lipids and carbohydrates, being crucial to maintaining energy homeostasis 
between mother and fetus. In this sense, at the preclinical level, it has been shown 
that it stimulates the production of the IGF-1 factor in maternal hepatocytes. It 
modulates intermediate metabolism by increasing food intake (orexigenic drive), 
which favors the increase in glucose available for transfer to the fetus and prevents 
the development of gestational diabetes caused by peripheral resistance, typical at 
this stage [1, 3].
Moreover, it has been suggested that it has a central role in intrauterine growth 
because more than 50% of neonates with stunted growth have shown a deficiency 
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in hPL levels. It is also believed that, by stimulating the uptake of glucose, glycerol, 
and free fatty acids, it could significantly participate in fat deposits, serving as an 
energy-saving mechanism for the fetus [1, 3].
Furthermore, it is well documented that in a normal state of pregnancy, insulin 
sensitivity decreases with the advance of the gestational state, which allows the 
fetus to maintain energy, an effect caused by a joint inhibitory action of peptide 
hormones (C-reactive protein, leptins, and hPL) on insulin levels causing dysfunc-
tion of pancreatic β-cells, named “diabetogenic condition.” However, a clinical study 
conducted by Ngala et al. (2017) showed that, throughout pregnancy, important 
maternal factors could predict the development of gestational diabetes mellitus 
(GDM) in addition to the already known factors of obesity and family history. 
In this sense, the levels of glucose, insulin, glycosylated hemoglobin (GHb), and 
hPL, among others, are increased in pregestational pregnant women, an effect not 
observed in non-diabetic pregnant women. Interestingly, under this condition, 
E2 and P4 levels decreased in pre-diabetic women, while in healthy women, the 
levels of both hormones are increased. On the other hand, between weeks 24–28 
of gestation, an increase in Progesterone, Estradiol, Leptins, GHb, and Fasting 
blood glucose (FBG) was observed in developing GMD, an effect associated with 
the increased insulin resistance. Controversially, although there is little informa-
tion linking hPL with the development of GDM, it is believed that the decrease 
in the levels of this hormone after delivery is associated with the reduction in 
glucose resistance and with the increased risk of diabetes-prediabetes in nursing 
 mothers [33, 34].
Interestingly, hPL participates in lactation by stimulating the breast epithelium, 
facilitating breast development during the gestational stage. In this process, both 
hormones (hPL and PRL) act in maternal behavior, suppressing stress responses in 
the last stage of pregnancy and lactation [1]. In this sense, it has been shown that 
dopaminergic neurons’ activity can be maintained by hPL [23].
All these results confirm the metabolic action of hPL in pregnancy and lactation, 
alone or together to other placental and maternal hormones.
8.  Human chorionic gonadotropic (hCG), the placental essential 
hormone
HCG is considered one of the essential hormones during gestational develop-
ment, having similarities with other members of the same family of glycoproteic 
proteins such as LH and pituitary FSH. Its synthesis is regulated by the luteal body 
and placenta, exercising a pleiotropic role during gestation by autocrine and para-
crine mechanisms [3]. It is possible to detect significant levels from day eight after 
fertilization, reaching its maximum levels around the tenth week of development. 
After which, it maintains at constant levels when the placenta is fully developed. At 
this point, the luteal body’s secretions are no longer necessary [3].
It participates in the process of steroidogenesis and in the restoration-mainte-
nance of the luteal body, where it acts as a relay system, whose purpose is to prevent 
menstruation by increasing the synthesis of P4, allowing that the embryo can be 
implanted in the uterine endometrium, ensuring pregnancy until placental produc-
tion of Progesterone is well established [3].
The hCG has also been shown to have a structure like Thyroid stimulating 
hormone (TSH) to bind to the same receptors, having implications for regulating 
thyrotropic activity. Preclinical studies have shown that maternal TSH decreases at 
the end of the third trimester of pregnancy. This decrease correlates with increased 
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placental hCG and fetal thyroxine-binding globulin (TGB) [1]. In vitro studies have 
shown that it can have angiogenic effects; it increases vascular-endothelial growth 
factor (VEGF) and placental microvascular endothelial cells [3].
Moreover, clinical studies have shown that it is also involved in the differentia-
tion of cytotrophoblast in syncytiotrophoblast, constituting an essential factor 
in the secretion of relaxing decidual production of PRL. On the other hand, it has 
androgenic properties. It can promote the synthesis of DHEA by the fetal adrenal 
cortex, regulating both testicular function and fetal male differentiation during the 
first weeks of gestation [35]. In addition, it has been suggested that it has partici-
pated in other functions; in the immune system, stimulates the production of the 
anti-inflammatory interleukins IL-8 and IL-10, and inhibits lymphocyte response, 
preventing rejection of the fetus, suggesting an immunosuppressive role of hCG 
during pregnancy; it stimulates testicular Leydig cells for testosterone production 
and provides nutrients and hormones for optimal maintenance of intrauterine 
microenvironment [3, 35]. So, the metabolic implications of this hormone sug-
gested it like a metabolic hormone in pregnancy.
9. Cortisol and glucocorticoids; is it just stress in pregnancy?
The secretion of cortisol levels during pregnancy is regulated by the placenta, 
which, by secreting the corticotropin-releasing hormone (CRH), produces an expo-
nential increase in cortisol from the eighth week of gestation up to three times above 
systemic values [5, 36]. It is present in both the maternal and fetal phases but at 
different levels; under normal conditions, cortisol levels reach 200 ng/ml at the end 
of pregnancy, while fetal levels range from around 20 ng/ml [37]. These differences 
are due to the presence of a natural barrier that prevents maternal cortisol, whose 
molecular composition can cross the placenta, quickly reaches fetal space [38, 39].
This barrier corresponds to the uterus/fetus interface and is mainly com-
posed of maternal decidua and fetal placenta chorion. Here the regulation of 
cortisol is carried out through placental glycoprotein P, as well as the enzyme 
11-β-hydroxysteroid-dehydrogenase (11-β-HSD) type 2 of trophoblastic and fetal 
cells, which inactivates cortisol by converting it into cortisone to avoid exposure 
of the fetus to high levels of cortisol [37, 40]. However, because of its role in organ 
maturation and labor, fetal cortisol increases towards the end of pregnancy by 
several mechanisms: a) decrease of 11-β-HSD type 2 in fetal tissues, b) increased 
synthesis of cortisol by the fetal adrenal gland, and c) increased 11-β-HSD type 1 in 
fetal tissues, which converts cortisone, into active cortisol [41].
As for the functions of cortisol during pregnancy, glucocorticoids (GC) have 
been described as participating in the processes of implantation and formation of 
decidua, as well as in fetal development and maturation, and initiation of childbirth 
[17, 36, 42]. Elevated levels of GC present during pregnancy are involved in the 
suppression of inflammation of the uterus, placenta, and fetal membranes, which 
contributes to maintaining the homeostasis necessary for the maintenance of preg-
nancy [42]. Moreover, recent evidence suggests that significant increases in cortisol 
levels play a critical role in the baby’s growth in the postnatal stage [43]. In this 
sense, studies have shown that high concentrations of cortisol during the fetal phase 
positively correlated with weight gain within the first five years of postnatal growth, 
indicating that the higher increase in placental cortisol levels, the more significant 
weight gain can be observed in children during this stage, suggesting that hormonal 
changes within the maternal-fetal environment have repercussions in post-birth 
stages, a highly relevant endocrinological aspect [43].
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Conversely, cortisol is also involved in developing pregnancy complications, 
being responsible for the so-called “Hypothalamic Stress Amenorrhea,” whose 
consequence is the generation of miscarriages [8, 44]. On the one hand, it has been 
shown that low maternal cortisol levels compromise the placenta’s structure. In 
contrast, elevated levels can lead to miscarriages, uterine contractions from placen-
tal CRH deregulation, the elevation of fetal cortisol levels, and obstetric alterations 
by activation of the HPA gland axis [14, 36, 38, 45]. In this sense, two main axes, the 
HPA, and the sympathetic nervous system-adrenal medulla exerts a negative effect 
on the reproductive system when activated in stressful situations. In this feedback 
mechanism, the CRH that is produced at the pituitary can act, in a short negative 
feedback mechanism, directly inhibiting GnRH at the hypothalamus.
Even more, cortisol act at the pituitary to inhibit the release of LH and FSH, and, 
consequently, inhibits steroidal ovarian hormones, Estrogen, and P4, resulting in 
abortion. It has been confirmed in preclinical and clinical studies, where exposure 
to stressors, such as noise, has been verified to induce miscarriages, with a signifi-
cant decrease in P4 levels [8, 44]. More interesting, stress increases the excitability 
of the sympathetic nervous system, resulting in a decrease in blood flow supply to 
the placenta caused placental hypoxia and increased generation of reactive oxygen 
species, causing damage to trophoblasts; the outer layer of the blastocyst, respon-
sible for providing nourishing to the embryo [44].
Finally, it has also been suggested that high cortisol levels could mediate a 
disbalance in T helper cells Th 1 and Th 2, with a specific impact in the decrease of 
adaptative immune system responses that allow the fetus’s maintenance. However, 
more studies are needed to confirm this [44]. So, it is evident that cortisol is not just 
a “stress hormone”; it has several functions supporting the MPFU.
10. Thyroid hormones in pregnancy; regulation by sex hormones?
During pregnancy, high estrogens and corticosteroids induce an increase in 
TGB levels in the liver, which is significant from week twenty of gestation, reach-
ing its maximum level from week twenty to twenty-four. The rise in TGB during 
the first half of pregnancy is related to further deiodination of the inner ring of 
the hormones T4 (Thyroxine) and T3 (Triiodothyronine) at the placenta, which is 
responsible for the physiological effect attributed to them [46, 47].
As far as the fetus is concerned, it has been shown that there are at least two 
mechanisms for it to contribute to thyroid hormones: the development of the fetal 
thyroid gland and the maternal thyroid gland. More interesting, the increase in 
concentrations of T4 in the first half of pregnancy and the expression of receptors 
to thyroid hormones in the brain, suggesting its participation in the development of 
brain structures of the fetus. Moreover, from weeks twelve-fourteen, in which the 
fetal thyroid begins to synthesize T4, its levels increase progressively, until reaching 
its maximum levels between week thirty-four to thirty-six, remaining elevated until 
the delivery time [46].
About iodine levels begin to be detected from ten to eleven weeks of gestation, 
a stage in which the fetal thyroid can concentrate. Around the twelfth week, the 
pituitary starts to produce and synthesize TSH and TRH (Thyrotropin-releasing 
hormone) by the hypothalamic neurons [46].
Before the fetal thyroid develops, the placenta has a particular involvement in 
maternal-fetal thyroid regulation. It is responsible for exchanging thyroid hormones 
to the fetus, suggesting an essential role in early fetal growth. Among the functions 
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attributed to thyroid hormones are the brain’s development and the acceleration of 
fetal pulmonary maturation. The effect has been demonstrated in preclinical and 
clinical models in which fetal pulmonary growth has been shown to increase after 
intraamniotic injection of T3 or T4. On the other hand, the effect at the brain level 
has been demonstrated in intrauterine hypothyroidism conditions. It is related to 
irreversible damage to the brain and mental disability in children born under these 
conditions [46, 47].
Interestingly, clinical studies conducted in children whose mothers suffered 
from hypothyroidism, a condition that occurs in 0.05–0.02% during pregnancy, 
have shown that these irreversible changes specifically affect neurodevelopment. In 
this sense, it has been demonstrated that any situation that leads to the development 
of clinical hypothyroidism (generally associated with Graves’ disease) and hypo-
thyroxinemia (associated with overtreatment of antithyroid drugs) that can occur 
during the first trimester of pregnancy can lead to a cognitive delay in children, 
learning disorders, maturational delay, encephalopathy, and seizures among other 
conditions [48].
Significantly, the increase in TSH, T3, and T4 during pregnancy could have 
protective effects against fetal anemia because it has been suggested that they may 
have cardiotonic effects by direct activation of the sympathetic-adrenal nervous 
system, in addition to being shown to stimulate the production of erythropoietin, 
which is involved in the production of red blood cells and therefore in the release of 
oxygen to tissues [47].
In this sense, it is fascinating to understand that sex hormones regulate the 
release of thyroid hormones and the vital functions involved, like brain develop-
ment, being crucial during pregnancy and childhood.
11. Conclusions
Pregnancy is a physiological state characterized by critical hormonal changes. 
Collective participation of the endocrine system is necessary to carry out adequate 
development and maintenance of both the mother and the fetus. This system is 
responsible for generating an optimal environment that provides an adequate 
microenvironment of communication between the maternal-placental-fetal unit, 
facilitating the exchange of nutrients, hormones, and oxygen, essential throughout 
the gestational period. These neuroendocrine processes are produced thanks to the 
synchronous and fluctuating production of sex hormones regulated by endocrine, 
paracrine, and autocrine mechanisms. Their function is essential before, during, 
and after the gestational period to ensure the fetus’s correct development and 
growth.
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